StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Quarterly ResultNov 5, 2026, 08:11 AM

Novavax Q3 Revenue $68M; Raises FY26 Revenue Guidance; Earns $125M Milestone

AI Summary

Novavax reported its third quarter 2026 financial results, with total revenue of $68 million, a slight decrease from the previous year. The company raised its full-year 2026 Non-GAAP Adjusted Total Revenue guidance to $400 million at the mid-point and improved its GAAP Combined R&D and SG&A expense guidance. A significant operational highlight was earning a $125 million milestone payment from Sanofi for the launch of a Phase 3 influenza-COVID-19 combination vaccine trial in Europe, with Sanofi also intending to initiate a U.S. trial in 2027. The net loss for the quarter narrowed significantly to $31 million from $202 million in the prior year's quarter.

Key Highlights

  • Novavax reported Q3 2026 total revenue of $68 million, a 3% decrease year-over-year.
  • Raised full-year 2026 Non-GAAP Adjusted Total Revenue guidance by $145 million to $400 million at mid-point.
  • Earned a $125 million milestone payment in October 2026 upon Sanofi's launch of Phase 3 influenza-COVID-19 combination vaccine trial in Europe.
  • Sanofi confirmed intent to initiate a U.S. Phase 3 influenza-COVID-19 combination vaccine trial in 2027.
  • Q3 2026 net loss was $31 million, compared to a net loss of $202 million in Q3 2025.
  • Cash, cash equivalents, marketable securities and restricted cash were $627 million as of September 30, 2026.
  • Differentiated C. difficile vaccine program anticipated to advance into the clinic as early as 2027.